A wave of after-hours activity swept through select biotech and medical device names Thursday, with several micro- and mid-cap stocks posting sharp gains following session-end catalysts, volume spikes, or pipeline updates. Below are key price moves and developments from RVPH, PEN, PALI, IOBT, RLYB, and VOR.Reviva Pharmaceuticals Holdings Inc. (RVPH) extended its explosive rally into after-hours trading Thursday, jumping 18.27% to $0.58 following a 35.1% surge during the regular session. The move came on a ...

Core Insights - Several biotech and healthcare stocks experienced significant after-hours gains on October 1, driven by technical momentum and recent clinical updates rather than new disclosures [1] Company Summaries - Zhongchao Inc. (ZCMD) saw a 14.04% increase in after-hours trading, rising to $1.30 from $1.14, despite no new filings or press releases [2] - AbCellera Biologics Inc. (ABCL) rose 11.41% in after-hours trading, closing at $6.64, following an 18.49% gain during the regular session, attributed to recent clinical trial progress [3][4] - Vor Biopharma Inc. (VOR) surged 9.53% in after-hours trading, recovering from a 19.42% drop during the regular session, with no new updates since a recent announcement regarding clinical data presentation [5] - Incannex Healthcare Inc. (IXHL) gained 6.48% in after-hours trading, partially recovering from a 6.94% drop, with the latest update showing positive Phase 2 trial results for PSX-001 [6] - Ovid Therapeutics Inc. (OVID) shares rose 8.03% in after-hours trading, building on a 5.38% gain during the regular session, with recent earnings report indicating a narrower net loss and higher revenue [7] - Bullfrog AI Holdings Inc. (BFRG) advanced 3.44% in after-hours trading, following a 3.57% rise during the regular session, after announcing an expansion of its sales and marketing team [8]

BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the Phase 3 study in China evaluating telitacicept in adults with primary Sjögren’s disease, a study sponsored by Vor’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as a late-breaking poster presentation at ACR Convergence 2025, being held October 24-29, 2025, at McCormick Place in Chi ...

BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the Phase 3 study in China evaluating telitacicept in adults with primary Sjögren’s disease, a study sponsored by Vor’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as a late-breaking poster presentation at ACR Convergence 2025, being held October 24-29, 2025, at McCormick Place in Chi ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, int ...

Vor Biopharma (NASDAQ:VOR) has been upgraded to Buy from Hold at Stifel as confidence in the company’s long-term potential has grown following prospects for its lead asset, telitacicept. The shares of the company are up 13% so far today. The ...

Dr. Khan brings decades of global medical affairs, commercial, and scientific leadership across multiple therapeutic areas including seven successful product launchesCAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer. Dr. Khan joins Vor Bio with over two decades of experience spanning medical ...

Group 1 - Vor Bio underwent a reverse stock split at a ratio of 20 for 1 to increase its per-share price by reducing the number of shares outstanding [1][6] - The company is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development for serious autoantibody-driven conditions [2][6] - Vor Bio plans to present 48-week clinical data from a Phase 3 study in China at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting on October 29, 2025 [3][6] Group 2 - Vor Bio is participating in the Stifel 2025 Virtual Immunology and Inflammation Forum, engaging in a fireside chat and hosting virtual one-on-one investor meetings [4] - The current stock price of Vor Bio is $1.52, with a market capitalization of approximately $192.6 million and a trading volume of 4,701,878 shares [5]

Core Viewpoint - RemeGen's telitacicept has shown promising results in treating generalized myasthenia gravis (gMG), with data from a 48-week open-label extension of a Phase III clinical study to be presented at the upcoming AANEM Annual Meeting, indicating its potential as a best-in-class therapy in this field [1][3]. Group 1: Clinical Study Results - The 24-week data from the Phase III study of telitacicept revealed that 98.1% of patients experienced a 3-point improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score, while 87% achieved a 5-point improvement in the Quantitative Myasthenia Gravis (QMG) score [3]. - The complete 48-week data presentation is expected to further emphasize telitacicept's efficacy and safety in treating gMG [3]. Group 2: Licensing and Development - In June 2025, RemeGen out-licensed telitacicept to Vor Bio, which is currently advancing a global multicenter Phase III clinical trial for gMG, with patient recruitment ongoing across multiple regions including the US, Europe, South America, and Asia-Pacific [4]. Group 3: Product Information - Telitacicept is the first-in-class injectable recombinant dual-target fusion protein that inhibits the binding of BLyS and APRIL cytokines to B cell receptors, addressing autoimmune diseases [5]. - The drug has already received approval in China for treating systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG) [5]. Group 4: Market Context - Generalized myasthenia gravis is a rare autoimmune disorder affecting approximately 90,000 patients in the US, 140,000 in Europe, and 29,000 in Japan, highlighting a significant unmet clinical need for effective therapies [7].

Company Overview - Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases [1][2] - The company is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization [2][3] Clinical Study Details - Vor Bio announced 48-week clinical data from a Phase 3 study in China evaluating telitacicept in adults with generalized myasthenia gravis [1] - The study demonstrated a placebo-adjusted 4.83-point improvement in the Myasthenia Gravis Activities of Daily Living scale (MG-ADL) at 24 weeks, which is the primary endpoint of the trial [3] Product Information - Telitacicept selectively inhibits BLyS (BAFF) and APRIL, two cytokines essential for B cell and plasma cell survival, thereby reducing autoreactive B cells and autoantibody production [3] - Telitacicept is already approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG) [4] Market Context - Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune neuromuscular disorder affecting approximately 90,000 people in the United States, 140,000 in Europe, and 29,000 in Japan [5] - There is a significant unmet need for new therapies that provide durable efficacy and a favorable safety profile for gMG patients [5] Upcoming Presentation - The clinical data will be presented as an oral presentation at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting on October 29, 2025 [1][2]